No Detail Found!

Effect of Erythropoiesis Stimulating Agents on Clinical Outcomes in Breast Cancer Patients: A Systematic Review of Randomised Controlled Trials

Author(s)
Saeeda Sabir Institute of Pharmacy, Lahore College for Women University, Lahore, Pakistan
Yusra Habib Khan Department of Clinical Pharmacy, Jouf University, Al-Jouf, Kingdom of Saudi Arabia
Maryam Khatoon Institute of Pharmacy, Lahore College for Women University, Lahore, Pakistan
Rabia Noreen Institute of Pharmacy, Lahore College for Women University, Lahore, Pakistan
Tauqeer Hussain Mallhi Department of Clinical Pharmacy, Jouf University, Al-Jouf, Kingdom of Saudi Arabia
Nayyab Jabeen Department of Medicine, Khalifa Gul Nawaz Teaching Hospital, MTI, Bannu, Khyber Pakhtunkhwa, Pakistan
Abstract
The impact of erythropoiesis stimulating agents (ESAs) on clinical outcomes among breast cancer patients is debatable. Current review is aimed to ascertain the efficacy of ESAs among breast cancer patients. Randomised controlled trials (RCTs) were electronically searched. Primary outcomes were mortality, blood transfusion requirements and thromboembolic events (TEEs); whereas, secondary outcomes were safety, tumor progression, anemia treatment, hemoglobin levels and quality of life (QOL). Out of 11 RCTs including 6,849 participants, 9 RCTs reported 2,312 deaths with overall mortality of 33.7%. Mortality reported for epoetin alfa (EA), epoetin beta (EB) and darbepoetin alfa (DA) was 41.24%, 73.1% and 8.99% respectively. TEEs reported for EA, EB and DA were 5.88%, 9.28% and 2.85%, respectively. Serious adverse events were 39.04%, 36.29%, 1.53% for EA, EB and DA, respectively. Tumor progression for EA and EB was 37.53% and 95.46%, respectively. No tumor progression was reported with DA. Erythropoietin reported no mortality, TEEs, serious ADRs and tumor progression. About 9% patients required transfusions during ESA therapy. Current evidence suggests that use of ESA reduces transfusion need but increases mortality and risks of TEEs.
Publication Details
Page(s) 292-298
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Breast cancer, Mortality, Survival, Chemotherapy, Anemia, Safety, Randomised controlled trials, Quality of lifTransfusion requirements, Erythropoiesis stimulating agents, Tumor progression
0

Citations

0

Downloads

71

Views